Immunovaccine Announces Leading Independent Proxy Advisory Firms Recommend Voting for Share Consolidation Related to Potential Nasdaq Listing
Although the approval of shareholders for the share consolidation is being sought at the meeting, the share consolidation would become effective at a date in the future to be determined by the board, if and when it is considered to be in the best interest of the company to implement the share consolidation. The board may determine not to implement the share consolidation at any time after the meeting without further action on the part of, or notice to, the shareholders, and there is no assurance whatsoever that the common shares of the company will be listed on the Nasdaq.
ISS and Glass Lewis Share Consolidation Recommendations
Among their positive recommendations FOR all items on the agenda, ISS and
Shareholders are reminded to vote their proxy before
For more information and assistance in voting your proxy, please contact
North Americatoll-free: 1-877-452-7184
- Local and international: 416-304-0211
- Email: email@example.com
Immunovaccine Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases.
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Corporation, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals.
T: (312) 961-2502 E: firstname.lastname@example.org
Pierre Labbé, Chief Financial Officer
T: (902) 492-1819 E: Plabbe@imvaccine.com
O: (415) 513-1284
T: (415) 515-4572 E: email@example.com
Source: Immunovaccine Inc.